Robert Stanley Sheldon, B.Sc., M.D., Ph.D., F.R.C.P.(C.)
Professor, Department of Medicine
Faculty of Medicine, University of Calgary
Tel: (403) 220-8191
Email:
Publications
Sheldon RS, Wright CJ, Duff HJ, Thakore E, Gillis AM, Roach DE. Mechanism of hypotensive transients associated with abrupt bradycardias in conscious rabbits. Can J Cardiol. 2007 (in press).
Sheldon RS, Sheldon AG, Serletis A, Connolly SJ, Morillo CA, Klingenheben T, Krahn AD, Koshman ML, Ritchie D, For The Investigators Of The Prevention Of Syncope StudyWorsening Of Symptoms Before Presentation With Vasovagal Syncope. J Cardiovasc Electrophysiol, 2007, (in press).
Sheldon RS, Sheldon AG, Connolly SJ, Morillo CA, Klingenheben T, Krahn AD, Koshman ML, Ritchie D. Age Of First Faint In Patients With Vasovagal Syncope. J Cardiovasc Electrophysiol. 2006 Jan;17(1):49-54.
Sheldon RS, Rose S, Connolly S, Ritchie D, Koshman ML, Frenneaux M. Diagnostic criteria for vasovagal syncope based on a quantitative history. European Heart Journal. 2006 Feb;27(3):344-50.
Sheldon RS, Connolly S, Rose S, Klingenheben T, Krahn A, Morillo C, Talajic M, Kus T, Fouad-Tarazi F, Ritchie D, Koshman ML. The Prevention of Syncope Trial (POST): A Randomized, Placebo-controlled Study of Metoprolol in the Prevention of Vasovagal Syncope. Circulation. 2006 Mar 7;113(9):1164-70.
Sheldon S. Primary prevention using ICDs may be cost-effective for people with left ventricular systolic dysfunction. Commentary 2. Evid Based Cardiovasc Med. 2006 Mar;10(1):56-8.
Raj SR, Rose S, Ritchie D, Sheldon RS on behalf of the POST II Investigators. The Second Prevention of Syncope Trial (POST II) - A Randomized Clinical Trial of Fludrocortisone for the Prevention of Neurally mediated syncope: Rationale and Study Design. Am Heart J. 2006 Jun;151(6):1186.e11-7.
ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–12.
Guo J, Zhan S, Somers J, Westenbroek RE, Catterall WA, Roach DE, Sheldon RS, Lees-Miller JP, Li P, Shimoni Y, Duff HJ. Decrease in Density of INa is in the Common Final Pathway to Heart Block in Murine Hearts Overexpressing Calcineurin. Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2669-79..
Serletis A, Rose S, Sheldon AG, Sheldon RS. Vasovagal Syncope In Medical Students And Their First-Degree Relatives. Eur Heart J. 2006 Aug;27(16):1965-70..
Benditt DG, Olshansky B, Wieling W on behalf of the Ad Hoc Syncope Consortium. An Unscientific ACCF/AHA Scientific Statement on Syncope. J Am Coll Cardiol 2006 Dec 19;48(12):2598-9.
Benditt DG for the Ad Hoc Syncope Consortium. The ACCF/AHA scientific statement on Syncope. A document in need of thoughtful revision. Europace. 2006 Dec;8(12):1017-21.
Raj SR, Roach DE, Koshman ML, Sheldon RS. Raj SR, Roach DE, Koshman ML, Sheldon RS. Standard Deviation of Sequential Five-Minute R-R Interval Means (SDANN) is a prognostic marker, but not necessarily an autonomic marker. J Am Coll Cardiol. 2006 Sep 19;48(6):1285-6.
Benditt DG, On behalf of the Ad Hoc Syncope Consortium. The ACCF/AHA Scientific Statement on Syncope a document in need of thoughtful revision. Clin Auton Res, 2006 16:363 -368.
Research Funding
CIHR
· “The Alerting Response and Vasovagal Syncope” 2001-2006
· “Physiologic Transients and Cardia Arrhythmias” 2002-2005
· “Prevention of Syncope Trial II” 2004-2009
Heart and Stroke Foundation of Alberta and Pfizer
· “SIRCAT: Statin-induced Regression of Cardiomyopathy Trial” 2006-2009 |
 |
|
|
